Bochuan Zhang1, Qingfeng Wang2, Chenghao Fu3, Chunying Jiang3, Shiliang Ma1,3. 1. College of Food Science and Technology, Shenyang Agricultural University, Shenyang 110161, China. 2. Basic Medical College Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China. 3. College of Bioscience and Biotechnology, Shenyang Agricultural University, Shenyang 110161, China.
Abstract
BACKGROUND: In this study, we aimed to explore the tumour associated immune signature of breast cancer (BC) and conduct integrative analyses with immune infiltrates in BC. METHODS: We downloaded the transcriptome profiling and clinical data of BC from The Cancer Genome Atlas (TCGA) database. The list of immune-related signatures was from the Innate database. The limma package was utilized to conduct the normalization, and we screened the differential immune signatures in BC. A univariate Cox regression model and the LASSO method were used to find the hub prognostic immune genes. The TAIG risk model was calculated based on the multivariate Cox regression results, and a receiver operating characteristic (ROC) curve was generated to assess the predictive power of TAIG. Moreover, we also conducted a correlation analysis between TAIG and the clinical characteristics. Additionally, we utilized the METABRIC cohort as the validation data set. The TIMER database is a comprehensive resource for performing systematic analyses of immune infiltrates across various malignancies. We evaluated the associations of immune signatures with several immune cells based on TIMER. Furthermore, we used the CIBERSORT algorithm to determine the fractions of immune cells in each sample and compared the differential distributions of immune infiltrates between two TAIG groups using the Wilcoxon rank-sum test. RESULTS: A total of 1,178 samples were obtained from the TCGA-BRCA database, but only 1,045 breast tumour samples were matched with complete transcriptome expression data. Meanwhile, we collected a total of 1,094 BC patients from the METABRIC cohort. We found a list of 1,399 differential immune signatures associated with survival, and functional analysis revealed that these genes participated in cytokine-cytokine receptor interactions, Th1 and Th2 cell differentiation and the JAK-STAT signalling pathway. The TAIG risk model was established from the multivariate Cox analysis, and we observed that high TAIG levels correlated with poor survival outcomes based on Kaplan-Meier analysis. The Kruskal-Wallis test suggested that high TAIG levels correlated with high AJCC-TNM stages and advanced pathological stages (P<0.01). We validated the well robustness of TAIG in METABRIC cohort and 5-year AUC reached up to 0.829. Moreover, we further uncovered the associations of hub immune signatures with immune cells and calculated the immune cell fractions in specific tumour samples based on gene signature expression. Last, we used the Wilcoxon rank-sum test to compare the differential immune density in the two groups and found that several immune cells had a significantly lower infiltrating density in the high TAIG groups, including CD8+ T cells (P=0.031), memory resting CD4+ T cells (P=0.026), M0 macrophages (P=0.023), and M2 macrophages (P=0.048). CONCLUSIONS: In summary, we explored the immune signature of BC and constructed a TAIG risk model to predict prognosis. Moreover, we integrated the identified immune signature with tumour-infiltrating immune cells and found adverse associations between the TAIG levels and immune cell infiltrating density. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: In this study, we aimed to explore the tumour associated immune signature of breast cancer (BC) and conduct integrative analyses with immune infiltrates in BC. METHODS: We downloaded the transcriptome profiling and clinical data of BC from The Cancer Genome Atlas (TCGA) database. The list of immune-related signatures was from the Innate database. The limma package was utilized to conduct the normalization, and we screened the differential immune signatures in BC. A univariate Cox regression model and the LASSO method were used to find the hub prognostic immune genes. The TAIG risk model was calculated based on the multivariate Cox regression results, and a receiver operating characteristic (ROC) curve was generated to assess the predictive power of TAIG. Moreover, we also conducted a correlation analysis between TAIG and the clinical characteristics. Additionally, we utilized the METABRIC cohort as the validation data set. The TIMER database is a comprehensive resource for performing systematic analyses of immune infiltrates across various malignancies. We evaluated the associations of immune signatures with several immune cells based on TIMER. Furthermore, we used the CIBERSORT algorithm to determine the fractions of immune cells in each sample and compared the differential distributions of immune infiltrates between two TAIG groups using the Wilcoxon rank-sum test. RESULTS: A total of 1,178 samples were obtained from the TCGA-BRCA database, but only 1,045 breast tumour samples were matched with complete transcriptome expression data. Meanwhile, we collected a total of 1,094 BC patients from the METABRIC cohort. We found a list of 1,399 differential immune signatures associated with survival, and functional analysis revealed that these genes participated in cytokine-cytokine receptor interactions, Th1 and Th2 cell differentiation and the JAK-STAT signalling pathway. The TAIG risk model was established from the multivariate Cox analysis, and we observed that high TAIG levels correlated with poor survival outcomes based on Kaplan-Meier analysis. The Kruskal-Wallis test suggested that high TAIG levels correlated with high AJCC-TNM stages and advanced pathological stages (P<0.01). We validated the well robustness of TAIG in METABRIC cohort and 5-year AUC reached up to 0.829. Moreover, we further uncovered the associations of hub immune signatures with immune cells and calculated the immune cell fractions in specific tumour samples based on gene signature expression. Last, we used the Wilcoxon rank-sum test to compare the differential immune density in the two groups and found that several immune cells had a significantly lower infiltrating density in the high TAIG groups, including CD8+ T cells (P=0.031), memory resting CD4+ T cells (P=0.026), M0 macrophages (P=0.023), and M2 macrophages (P=0.048). CONCLUSIONS: In summary, we explored the immune signature of BC and constructed a TAIG risk model to predict prognosis. Moreover, we integrated the identified immune signature with tumour-infiltrating immune cells and found adverse associations between the TAIG levels and immune cell infiltrating density. 2019 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Tumour-associated immune signature; breast cancer (BC); immune infiltrates; prognosis
Authors: Mette S van Ramshorst; Erik van Werkhoven; Ingrid A M Mandjes; Margaret Schot; Jelle Wesseling; Marie-Jeanne T F D Vrancken Peeters; Jetske M Meerum Terwogt; Monique E M Bos; Hendrika M Oosterkamp; Sjoerd Rodenhuis; Sabine C Linn; Gabe S Sonke Journal: Eur J Cancer Date: 2017-02-10 Impact factor: 9.162
Authors: Yibin Yang; Arthur L Shaffer; N C Tolga Emre; Michele Ceribelli; Meili Zhang; George Wright; Wenming Xiao; John Powell; John Platig; Holger Kohlhammer; Ryan M Young; Hong Zhao; Yandan Yang; Weihong Xu; Joseph J Buggy; Sriram Balasubramanian; Lesley A Mathews; Paul Shinn; Rajarshi Guha; Marc Ferrer; Craig Thomas; Thomas A Waldmann; Louis M Staudt Journal: Cancer Cell Date: 2012-06-12 Impact factor: 31.743
Authors: Marye J Boers-Sonderen; Lioe-Fee de Geus-Oei; Ingrid M E Desar; Winette T A van der Graaf; Wim J G Oyen; Petronella B Ottevanger; Carla M L van Herpen Journal: Target Oncol Date: 2014-03-01 Impact factor: 4.493
Authors: Charles G Mullighan; Salil Goorha; Ina Radtke; Christopher B Miller; Elaine Coustan-Smith; James D Dalton; Kevin Girtman; Susan Mathew; Jing Ma; Stanley B Pounds; Xiaoping Su; Ching-Hon Pui; Mary V Relling; William E Evans; Sheila A Shurtleff; James R Downing Journal: Nature Date: 2007-04-12 Impact factor: 49.962
Authors: Colt A Egelston; Christian Avalos; Travis Y Tu; Diana L Simons; Grecia Jimenez; Jae Y Jung; Laleh Melstrom; Kim Margolin; John H Yim; Laura Kruper; Joanne Mortimer; Peter P Lee Journal: Nat Commun Date: 2018-10-16 Impact factor: 14.919
Authors: Theodoros Foukakis; John Lövrot; Alexios Matikas; Ioannis Zerdes; Julie Lorent; Nick Tobin; Chikako Suzuki; Suzanne Egyházi Brage; Lena Carlsson; Zakaria Einbeigi; Barbro Linderholm; Niklas Loman; Martin Malmberg; Mårten Fernö; Lambert Skoog; Jonas Bergh; Thomas Hatschek Journal: Br J Cancer Date: 2018-01-25 Impact factor: 7.640